Is it Time to Dump Bio Path Holdings Inc (BPTH) Stock After it Is Lower By 6.31% in a Week?

Bio Path Holdings Inc (BPTH) stock is lower by 6.31% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Bio Path Holdings Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on BPTH!

See Full BPTH Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With BPTH Stock Today?

Bio Path Holdings Inc (BPTH) stock is lower by -0.74% while the S&P 500 is higher by 0.14% as of 2:42 PM on Thursday, Mar 28. BPTH is down -$0.03 from the previous closing price of $4.04 on volume of 37,773 shares. Over the past year the S&P 500 is up 32.35% while BPTH is down -87.77%. BPTH lost -$33.64 per share in the over the last 12 months. To screen for more stocks like Bio Path Holdings Inc click here.

More About Bio Path Holdings Inc

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. Click Here to get the full Stock Report for Bio Path Holdings Inc stock.